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Abstract
Purpose of Review To give an update on the emerging role of cardiac magnetic resonance imaging in the evaluation of patients
with heart failure with preserved ejection fraction (HFpEF). This is important as the diagnosis of HFpEF remains challenging and
cardiac imaging is pivotal in establishing the function of the heart and whether there is evidence of structural heart disease or
diastolic dysfunction. Echocardiography is widely available, although the gold standard in quantifying heart function is cardiac
magnetic resonance (CMR) imaging.
Recent Findings This review includes the recently updated 2016 European Society of Cardiology guidelines on diagnosing
HFpEF that define the central role of imaging in identifying patients with HFpEF. Moreover, it includes the pathophysiology in
HFpEF, how CMR works, and details current CMR techniques used to assess structural heart disease and diastolic function.
Furthermore, it highlights promising research techniques that over the next few years may becomemore used in identifying these
patients.
Summary CMR has an emerging role in establishing the diagnosis of HFpEF by measuring the left ventricular ejection fraction
(LVEF) and evidence of structural heart disease and diastolic dysfunction.
Keywords Cardiac magnetic resonance (CMR) . Diastolic dysfunction . Left ventricular hypertrophy . Left atrial enlargement
Introduction
The diagnosis of heart failure with preserved ejection fraction
(HFpEF) remains challenging as clinical symptoms and signs
are nonspecific [1]. Cardiac imaging is pivotal as the recently
updated European Society of Cardiology (ESC) guidelines
defined the diagnostic criteria for HFpEF as a left ventricular
ejection fraction (LVEF) that is preserved with either evidence
of diastolic dysfunction or structural heart disease, typical
symptoms and signs of heart failure (HF), and raised natriuret-
ic peptides [2••]. Practically, echocardiography is widely used
with up-to-date recommendations for assessment of diastolic
function [3], although these are indirect assessments of LV
filling and lack characterization of myocardial tissue.
Cardiac magnetic resonance (CMR) imaging represents the
gold standard in quantification of LVEF [4] and is increasingly
used in the assessment of HF due to its unique, precise, non-
invasive phenotypic characterization with high reproducibility
and sufficient spatial and temporal resolution [5]. The role of
CMR in characterizing diastolic function has not been fully
established clinically, although it is a class I indication for a
CMR in HF patients with poor acoustic windows, partly due
to the need for additional sequence acquisitions and time-
consuming image analysis and post-processing. This review
evaluates the pathophysiology of HFpEF, how CMR works,
current CMR techniques used to assess diastolic function, and
highlights promising research techniques.
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Pathophysiology of HFpEF
The exact pathophysiology of HFpEF remains uncertain and
is likely due to diastolic dysfunction, impaired systolic func-
tion on exercise, abnormal ventricular-arterial coupling, in-
flammation and endothelial dysfunction, chronotropic incom-
petence, altered myocardial energetics and peripheral skeletal
muscle metabolism and perfusion, and pulmonary hyperten-
sion and renal insufficiency [6••]. Only recently has it been
convincingly demonstrated that HFpEF represents more than
a sum of all its comorbidities and is a condition in its own right
[7]. Despite variations in pathophysiology, impaired diastolic
ventricular filling is consistently reported across all patients,
caused by increased stiffness of the left ventricle, impaired
atrial-ventricular conduction of blood, and decreased relaxa-
tion capability of the myocytes [6••, 8].
What Is Diastolic Dysfunction?
Diastole is the time taken for the left ventricle to fill between
the closure of the aortic valve and the closure of the mitral
valve. During this time, blood flows from the atria to the
ventricles due to the pressure difference between the chambers
with atrial contraction contributing to the final part of ventric-
ular filling. Diastole is an active, ATP-consuming myocardial
process. LV filling and the transmitral pressure gradient are
determined by the LVand atrial geometry, loading conditions,
viscoelastic properties, pericardial restraint, valve function,
heart rate, and temporal synchronization of the atrial and ven-
tricular contraction.
Diastolic dysfunction is classified into four phases [9],
Fig. 1. In grade 1 diastolic dysfunction, the proportion of LV
filling occurring in the early phase of diastole is reduced.
Pressure in the left atrium increases as the diastolic function
reduces further (grade 2). Grade 3 dysfunction occurs when
there is restrictive filling due to impaired relaxation with ele-
vated filling pressure and impaired LV compliance. With the
Valsalva maneuver, the impaired filling can be reversed.
Grade 4 diastolic dysfunction represents irreversible restric-
tive filling.
How CMR Works
CMR uses a magnetic field, approximately 30,000 times
stronger than the earth’s magnetic field, to align the nuclear
magnetization of hydrogen atoms that are abundant in the
human body. Image contrast is generated by the hydrogen
nuclei being intermittently excited by radiofrequency pulses,
resulting in longitudinal and transverse relaxation times that
are characteristic for different tissues. The CMR sequence
details the instructions for the radiofrequency pulses, timed
data acquisitions, and magnetic gradient field switches. Spin
echo sequences are mainly used for anatomic imaging and
tissue characterization, whereas gradient echo sequences are
used to acquire moving images. To prevent artifacts from car-
diac and respiratory motion, images are gated to the R wave of
the electrocardiogram and acquired in end-expiratory breath
hold. Intravenous gadolinium chelated contrast agents are
used to identify areas of scar or fibrosis, as a lengthened wash-
out indicates reduced functional capillary density in the irre-
versibly injured myocardium.
Current CMR Measurements to Assess Diastolic
Dysfunction
In assessing a patient with HF symptoms, the LVEF first needs
to be calculated. The current techniques to assess diastolic
dysfunction include measuring left atrial enlargement (LAE),
left ventricular hypertrophy (LVH), mitral inflow pattern, pul-
monary vein assessment, LV time volume relations, LV myo-
cardial tagging, flow propagation velocity, and calculating T1/
myocardial fibrosis, Fig. 2.
Left Atrial Size
Left atrial (LA) size, volume, and wall mass can be accurately
measured by CMR, and Simpson’s volumetric method has
always been considered the gold standard for measuring atrial
volumes [9]. LA volume can be measured accurately from
CMR imaging using the biplane area-length (BAL) technique
2 and 4 chamber images with the following equation: LA
volume (ml) = (0.85 × A2C × A4C)/L (where A2C and A4C
are the LA areas on the 2 chamber and 4 chamber views, and L
is the shorter length of the LA, from either the 2 or 4 chamber).
Recent work in patients with HFpEF has shown that the CMR
BAL technique is as accurate as CMR volumetric Simpson’s
method, with echocardiography BAL technique less accurate
than CMR volumetric assessment particularly with LA dilata-
tion and in patients with atrial fibrillation [10]. However, the
BAL techniques were not compared for echocardiography and
CMR. The size of the atrium varies during the cardiac cycle
but only maximal LA size is typically reported clinically.
Body size is a major determinant of atrial size with little var-
iation noted with gender [11].
The left atrium (LA) has three functions: during ventricular
systole, it acts as a reservoir receiving blood from the pulmo-
nary veins and storing energy in the form of pressure; during
early diastole, it acts as a conduit for transfer of blood into the
left ventricle via a pressure gradient and finally, it has a con-
tractile function, augmenting the LV stroke volume. In pa-
tients with normal diastolic function, the relative contribution
of the reservoir, conduit, and contractile function of the atria to
the LV filling is approximately 40, 35, and 25%, respectively
[12].With abnormal LV relaxation, the relative contribution of
atrial reservoir and contractile function increases, and conduit
function decreases. The atria enlarge in response to both
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pressure and volume overload. Pressure overload is usually
secondary to increased atrial afterload, either mitral valve dis-
ease or LV dysfunction, and is uniformly accompanied by
abnormal myocyte relaxation. Volume overload, however,
caused by athletic hearts, anemia, and mitral regurgitation
can cause atrial enlargement and is normally associated with
normal ventricular myocardial relaxation.
Atrial size is known to be prognostic; more than 32 ml/m2
is associated with increased incidence of heart failure indepen-
dent of age, LV hypertrophy, diabetes, hypertension, myocar-
dial infarction of mitral inflow velocities [13]. However there
is little evidence on the diagnostic and prognostic value of left
atrial volume in HFpEF patients [14], although recent evi-
dence suggests that LA function (measured by ejection
Fig. 1 Classification of diastolic dysfunction
Fig. 2 Anatomy in blue,
abnormalities in HFpEF in white
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fraction) has been shown to be associated with mortality out-
comes [15] and LAE was associated with the presence of
dyspnea [16].
Left Ventricular Hypertrophy
The Framingham Study reported that increased left ventricular
(LV) mass is associated with a significant excess of cardiovas-
cular mortality and morbidity, independent of hypertension of
the presence of coronary artery disease [17, 18]. Left ventric-
ular hypertrophy (LVH) is the most common structural abnor-
mality in patients with HFpEF. It is the response of myocytes
to various stimuli leading to myocyte hypertrophy, such as
increased mechanical load, neurohumoral activation, and cy-
tokines associatedwith arterial hypertension, diabetes, chronic
renal impairment, and other comorbidities [19].
Practically, LVH can be considered as concentric remodel-
ing (enlarged heart with normal relative wall thickness), con-
centric hypertrophy (increased relative wall thickness with
normal LV diameter), or eccentric remodeling (increased rel-
ative wall thickness with increased LV diameter). The accura-
cy of CMR has been validated ex vivo using post-mortem
hearts [20, 21] and it is more reproducible than both M mode
and 2D echocardiography [22].
Mitral Inflow Pattern
One of the most widely applied techniques in assessing LV
diastolic function is the evaluation of the transmitral inflow of
pulmonary venous flows using Doppler echocardiography.
These results are load-dependent and can change dramatically
with only minimal changes in heart rate or preload, and so not
evaluate LV relaxation directly.
Despite these limitations, phase contrast MRI is an attrac-
tive alternative to echocardiographic pulsed wave Doppler as
it allows both quantitative assessment of blood velocity and
optimal positioning in 3D space of the tomographic plane of
interest ensuring accurate alignment and measurements. The
acquisition plane is typically perpendicular to the flow direc-
tion at the position of the mitral valve at end systole. Data is
retrospectively ECG gated and can be acquired either free
breathing or with a breath hold. Thirty to 40 cardiac phases
are reconstructed resulting in a typical effective temporal res-
olution of the time velocity curve of 20–30 ms.
A time-resolved acquisition with velocity encoding per-
pendicular to this plane results in a time velocity curve
representing one average cardiac cycle. The waveform analy-
sis results in quantification of the early (E) and atrial (A) peak
filling velocities, E/A ratio, and deceleration time of the E
peak filling velocity. These can be used to classify different
grades of diastolic function [9, 23].
When compared to echocardiographic results, the results of
phase contrast CMR results correlated 100%, although E and
A velocities were found to be systematically lower.
However, the CMR acquisition of velocities in a pulsatile
flow phantom correlated correctly. These differences in
absolute values reflect differences in the nature of acquisi-
tion and did not result in any misclassification of diastolic
flow abnormalities between modalities [24]; echo data is
collected over one cardiac cycle, whereas CMR data is
effectively averaged overall several cycles. These acquisi-
tions take between 20 s and 3 min.
One challenge in CMR, however, is that the acquisition
plane remains fixed during the cardiac cycle and does not
move with the cyclical motion of the mitral annulus.
Acquisition techniques have been introduced using mov-
ing slice velocity mapping [25] and three-dimensional
three-directional velocity encoding [26]. These have
shown better agreement with echo Doppler when discrim-
inating restrictive filling patterns from other grades of dia-
stolic dysfunction [27].
Pulmonary Vein Assessment
Phase contrast MRI can also assess pulmonary veins. Rathi
et al. found that only 68% of echo cases were able to assess the
pulmonary veins, compared to 100% with CMR [24]. The
blood flow waveforms of the pulmonary veins provide impor-
tant information on diastolic function as LV filling and com-
pliance, left atrial preload, and contractility all influence the
left atrial filling pattern. Waveform analysis of the pulmonary
venous time velocity curve includes the peak systolic velocity
(S), peak anterograde diastolic velocity (D), and the peak atrial
reversal velocity (Ar) in late diastole. Often there are two
ventricular systolic velocity peaks, S1 and S2. S1 is related
to atrial relaxation and S2 to atrial stroke volume and pulse
wave propagation in the pulmonary artery. For this reason, S2
should be used to determine S/D ratio as a measure of diastolic
function. Just like transmitral Doppler, the sample is placed
0.5 cm into the right upper pulmonary vein and flow velocity
indices are influenced by age, although changes in LV filling
and compliance affect D velocity more. Ar velocity increases
with age but this does not usually exceed 35 cm/s and so
values above this suggest increased LVend-diastolic pressure
[28]. A difference in Ar-A duration > 30 ms indicates elevated
LVend-diastolic pressure [23].
LV Time Volume Relations
The LV time-volume relation is recorded from a series of
breath-held time-resolved parallel short-axis planes or a
radial stack of long-axis planes. Segmenting and summat-
ing the endocardial borders results in the end-diastolic and
end-systolic LV volumes. The stroke volume and systolic
function can be calculated from the difference between the
end-diastolic and end-systolic volumes. Early peak filling
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rate, time to peak filling rate, and atrial filling fraction can
also be calculated from this information. Diastolic dys-
function is associated with decreased peak filling rates
and increased time to peak filling rates. Despite improve-
ments in the definition of endocardial borders and the use
of automated segmentation [29], the accuracy remains too
low to use in clinical practice [30] and these parameters
have limited use.
LV Myocardial Tagging
It is possible to label or “tag” myocardium by selective satu-
ration pulses in specific regions in planes perpendicular to the
imaging plane, Fig. 3. Tag lines appear as black lines due to
the saturation of signal from protons and they last for several
hundred milliseconds. These lines can be tracked throughout
the cardiac cycle, enabling calculations in longitudinal, radial,
and circumferential directions, and are obtained every 20 mil-
liseconds resulting in high temporal resolution. The chal-
lenges that have prevented this technique from being intro-
duced widespread clinically are low signal to noise ratio, long
acquisition times, limited availability of validated post-
processing software, and that the tag lines fade during the
cardiac cycle, with 3T better than 1.5T due to longer T1 and
so longer persistence of the tag.
Edvardsen et al. demonstrated an association with regional
diastolic dysfunction in 218 asymptomatic patients with left
ventricular hypertrophy who had no evidence of clinical car-
diovascular disease or LV dysfunction [31]. More recent work
has been directed at feature tracking, a method of post-
processing routine cine acquisitions to provide quantitative
measurements of circumferential and radially directed wall
strain. However, inter-study reproducibility has been shown
to be poor for segmental and long-axis analyses of strain [32].
Additionally, displacement-encoded stimulated echoes
(DENSE) and strain-encoded imaging (SENC) applications
have both been used.
Flow Propagation Velocity
The flow propagation velocity (Vp) is a measure of the LV
suction force that has been attributed to LV relaxation. In
addition to diastolic function, variables such as flow field,
viscoelastic properties, inertial force, LV geometry, systolic
function, mitral valve function, and LV contractile function
influence intraventricular flow. AVp > 50 cm/s in echocardi-
ography is considered to be normal. Attempts with three-
dimensional three-directional velocity encoding CMR may
provide quantitative information on the intraventricular blood
flow field, although long acquisition times may limit the uni-
versal uptake of this technique [33].
Myocardial Fibrosis and Extracellular Volume
Measurements
Myocardial fibrosis is a pathological increase in the myo-
cardial collagen content caused by increased collagen syn-
thesis in the interstitium (resulting in diffuse myocardial
fibrosis) or myocyte replacement (resulting in scarring)
[34]. Increased diffuse myocardial fibrosis is a major de-
terminant of altered diastolic filling and systolic pumping
function of the LV. As myocardial stiffness increases in
line with the development of fibrosis, there is subsequent
deterioration in both systolic and diastolic function. The
pathophysiology of accumulating collagen content is di-
verse [34]. In HFpEF patients, there is increased collagen
synthesis with elevated serum fibrotic biomarkers [35].
There has been controversy as to whether HFpEF patients
have a higher collagen volume fraction (CVF). Borberly
et al. looked at endomyocardial biopsies taken from
HFpEF patients and demonstrated a higher CVF com-
pared to nonHFpEF patients [36]. Although, Aoli et al.
studied 172 HFpEF and HFrEF patients’ endomyocardial
biopsies and found no statistically significant difference
between CVF in the HFpEF and HFrEF population and
that CVF did not predict outcome in HFpEF patients [37].
More recently, myocardium measured directly from
HFpEF patients has been found to have a significant in-
crease in insoluble and total collagen, as well as CVF
when compared to patients with hypertension but no
HFpEF [38•].
Diffuse interstitial fibrosis, a precursor for replacement fi-
brosis, is not detected by late gadolinium enhancement but
correlates with T1 mapping, which allows a quantitative as-
sessment of diffuse cardiac fibrosis and estimations of the
extracellular matrix volume (ECV) [39–41]. Studies have val-
idated T1 mapping and ECVestimation by CMR against his-
tology in a variety of conditions including aortic stenosis,
hypertrophic cardiomyopathy, and amyloidosis, reporting a
good correlation with myocardial collagen content (r =
0.51~0.81) [42].
T1 mapping reflected diffuse fibrosis in 25 heart failure
patients (LV ejection fraction 35 +/− 3.3%) [41]. In 2014,
Mascherbauer et al. demonstrated T1 times, left atrial size,
and pulmonary vascular resistance were significantly associ-
ated with cardiac events in 100 suspected HFpEF patients.
The authors concluded that post-contrast T1 times are associ-
ated with prognosis and should be considered a possible
HFpEF biomarker [43]. Another study looked at 62 patients
with HFpEF defined as signs and symptoms of heart failure,
LVEF > 45% and LV diastolic dysfunction documented by
tissue Doppler echocardiography (mean septal and lateral mi-
tral annular velocity < 8 cm/s) [44]. The authors found a sig-
nificantly higher ECV in patients with both HFrEF and
HFpEF, compared to patients without heart failure. In
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addition, ECV correlated with peak filling rate in the HFpEF
population despite no correlation identified in the HFrEF
population.
Emerging CMR Imaging Techniques
Despite recent development in these techniques and the intro-
duction of updated ESC diagnostic guidelines, no one assess-
ment is definitive in detecting patients with HFpEF. Recent
research in pulse wave velocity, MR elastography, and 4D
flow assessment looks promising in these patients.
ME Elastography
It has been hypothesized that magnetic resonance
elastography (MRE) may act as a biomarker for patients with
HFpEF as it uses mechanical shear waves to quantitatively
assess the stiffness of tissues. Applying stress to a material
Fig. 3 a Tag image of the
myocardium; b 2 chamber view; c
4 chamber view; d short-axis
image; e tag output for 17
segments of the LV showing
deformation against time
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results in a strain response of that tissue which can be mea-
sured. When the material is subjected to periodic shear, shear
waves occur. The pair of equal forces acting in opposite di-
rections along the two faces of the layer causes a change of
shape, even though the volume remains unchanged. If the
medium is elastic, then the layer will resume its original shape
after the shear wave has passed. A wave is propagated as the
adjacent layers undergo transient shear with equal forces act-
ing in opposite directions, and then resume their original
shape. MR elastography has been shown to map the shear
stiffness of soft tissues [45]. In 2017, Arani et al. reported that
16 patients with cardiac amyloid had increased myocardial
stiffness in comparison to 11 volunteers (median 11.4 kPa
with range of 9.2–15.7, median 8.2 kPa with a range of 7.2–
11.8, respectively, at a vibration frequency of 140 Hz) [46•].
4D Flow Assessment
3D phase contrast MRI, known as 4D CMR, allows volumet-
ric flow imaging in a single acquisition. Complex blood flow
patterns can be intuitively visualized as they unfold inmultiple
dimensions over time. Diastolic dysfunction is associated with
abnormal intracardiac blood flow and it is possible to analyze
quantitatively with 4D flow. This analysis can identify and
monitor diastolic dysfunction. Blood transiting the left ventri-
cle can be divided into four separate functional components:
direct flow which enters and exits a single heartbeat, retained
inflow which enters but does not exit, delayed ejection flow
which exits on the subsequent heartbeat, and the residual vol-
ume that resides in the ventricle for at least two cardiac cycles.
Investigation of these relative percentages of flow components
and the kinetic energy and momentum will allow a refined
analysis of the dynamic of ventricular filling and ejection.
4D flow can uniquely identify flow differences not seen with
conventional hemodynamic assessment. Diminished direct
flow and reduced kinetic energy of the direct flow at end
diastole can be identified. As a consequence, increased work-
load is placed on the left ventricle to eject the same stroke
volume.
Limitations of CMR
There is no doubt that CMR offers excellent spatial resolution
and is the gold standard for assessment of LV volumes and
myocardial tissue characterization. However, not all depart-
ments have access to CMR imaging and the scanners are more
expensive that transthoracic echocardiography, as well as tak-
ing longer. Furthermore, patient selection is critical as some
patients cannot tolerate the scan due to claustrophobia (al-
though there are limited scanners that patients are not
enclosed) and patients with certain implants are not allowed
in the scanner. There is a small risk of anaphylaxis due to
contrast, and patients with renal impairment need reduced
doses with contrast administration being contraindicated if
the GFR < 15 mls/min.
Conclusion
Cardiac MRI is fundamental in the assessment and character-
ization in heart failure patients. Despite challenges with long
acquisition times and challenges in post-processing, CMR has
a pivotal role in measuring LV systolic function and identify-
ing left atrial enlargement and left ventricular hypertrophy, as
well as other measures of diastolic function.
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